The findings don’t suggest laughter is a cure-all. What they do suggest is something more useful for everyday life: laughter is a low-cost, low-risk way to nudge the nervous system out of threat mode and back toward regulation — especially when it’s shared with other people.

How Laughter Works

When you laugh, you’re not only reacting emotionally — you’re recruiting multiple systems at once. Your breathing changes (often becoming deeper and more rhythmic), your face and core muscles contract, and your autonomic nervous system (the system that controls “fight-or-flight” and “rest-and-digest” can shift gears. That matters because so many stress-related problems — poor sleep, tension, irritability, rumination — ride on chronic activation of the stress response.

One of the most consistent biological signals researchers track is cortisol, a stress hormone that tends to rise with ongoing strain and can affect sleep, immune functioning, and mood. A meta-analysis found that spontaneous laughter was associated with greater reductions in cortisol than usual activities, suggesting a genuine stress-regulation effect rather than just a subjective feeling of relief.

This is important because it ties the “I feel better” experience to a measurable stress marker. So it’s not all in your head because it is biologically measurable. If you want to think of it another way, laughter is the non-prescription medication that you should take as often as possible. I’ve written about this before and have recommended it to all my college students and my patients.

I am a great believer that laughter plays a significant role in our lives. And you don’t need to wait to be in a group to laugh, because laughing even while alone serves a superior purpose in health maintenance. Does that mean you spontaneously laugh out loud for no reason? It could be so, but you could also use things like TV shows, films, things you’ve read, or anything that is humorous and makes you laugh.

Laughter can also influence brain chemistry linked to mood and pain. While the exact pathways are complex, reputable clinical education sources point to laughter’s relationship with endorphins and other neurochemicals involved in well-being and reward. That doesn’t mean laughter replaces medication or therapy when those are needed. But it helps explain why, in the moment, laughter can feel like a small reset — less tightness in the chest, a clearer head, a slight loosening of emotional grip.

There’s also a social pathway that may be just as powerful. Laughter is contagious for a reason: it signals safety and shared understanding. When people laugh together, they often feel more connected, and that sense of belonging can buffer stress. A 2023 Harvard Gazette feature — grounded in clinical expertise — highlights laughter’s role in lifting spirits and strengthening connection, which aligns with what many mental health clinicians see in real life: isolation amplifies distress, and connection softens it.

What Current Studies Say

The strongest modern evidence comes from controlled “laughter-based interventions.” These include laughter therapy, humor interventions, and laughter yoga (which combines intentional laughter with breathing and simple movement). These approaches are especially useful for research because they can be delivered consistently and compared with control conditions.

Mental health outcomes are promising, though not uniform across every study. A 2024 meta-analysis of randomized controlled trials examined laughter and humor interventions in adults and found improvements in outcomes such as depression and sleep, with more mixed findings for anxiety depending on the population and the type of intervention. That pattern — clearer benefit for mood and sleep than for anxiety — shows up elsewhere too.

For example, a 2022 randomized study on online laughter therapy in first-year nursing students reported reductions in depression, while anxiety effects were less consistent. This doesn’t mean laughter can’t help anxiety. It suggests that anxiety may require either longer interventions, more targeted techniques, or additional supports (like cognitive strategies and exposure-based tools), whereas mood and sleep may respond more readily to the stress-relief and social “unclenching” that laughter provides. There are benefits, and there are limitations, but I suggest the benefits are worth trying.

On the physical side, one area getting attention is cardiovascular functioning. A well-known line of research has explored how laughter may influence blood vessel function and circulation — factors linked with heart health. A British Heart Foundation article discussing this body of work describes findings such as improved arterial function and reduced inflammation markers following laughter-based approaches. Even when studies are small, the direction of effect is noteworthy because cardiovascular health is so closely tied to stress physiology. Worried a bit about your heart health? Okay, then you have to try laughing.

Workplace and burnout-related outcomes have also been studied. A 2024 systematic review focused on nurses and nursing students reported that laughter yoga interventions were associated with reductions in stress and burnout measures, along with improvements in mood-related outcomes in several included studies. These are high-stress groups, so the fact that laughter-based practices can move the needle at all suggests they may be a helpful “adjunct” — a supportive add-on rather than a standalone solution.

One caution that shows scientific maturity in this field is that researchers are increasingly clear about limits. A review on laughter and longevity argues that laughter is biologically plausible as a supportive factor — through stress modulation, social connection, and healthier behavioral patterns — but also emphasizes that the science is still developing and needs stronger, larger trials. That’s the responsible takeaway: laughter looks beneficial, especially for stress and mood, but it’s not magic, and it’s not a substitute for medical or psychological care.

Making Laughter a Health Habit

If laughter is “medicine,” it’s not a pill — it’s a behavior. And like most health behaviors, it works best when it’s realistic, repeatable, and emotionally safe.

Start by letting go of the idea that you must feel joyful first. Some laughter-based methods use intentional laughter that can become genuine once the body loosens up. This can be useful for people who feel flat, burnt out, or socially guarded. In a sense, it’s similar to other behavioral activation ideas: you don’t wait for motivation; you create conditions that make a better mood more likely. Research on structured laughter interventions suggests that even planned laughter can improve well-being.

Next, focus on the social dose. Watching something funny alone can help, but shared laughter adds warmth, belonging, and the quiet reassurance of “I’m not doing life by myself.” If someone is depressed, grieving, or chronically stressed, that social signal may be part of the benefit, not just the joke itself.

Finally, keep it grounded. Laughter is not appropriate in every moment, and forcing it in the face of serious pain can feel invalidating. A helpful guideline is to use laughter as a release valve, not a way to deny reality. It can sit alongside hard feelings rather than replacing them. And if laughter triggers discomfort — some people feel vulnerable when they laugh freely — gentle exposure is fine: smaller moments, safer people, and content that doesn’t leave you feeling ashamed afterward.

Taken together, the current research implies something simple: laughter is a meaningful stress-buffer with measurable biological signals, credible mental health benefits (especially mood and sleep), and potential cardiovascular upside — most effective as a complement to good care and good habits, not a replacement for them.

The post Laugh and Learn to Live This Year appeared first on Medika Life.

The FemTech Foundation—and Fault Lines

In 2015, fewer than 300 ventures focused on women’s health existed. That number has tripled to 942, according to the Galen Growth HealthTech Alpha™ platform. These ventures now span the female health continuum—gynecology, menopause, oncology, cardiovascular disease, mental health and beyond.

Yet the investment tide has not fully turned in FemTech’s favor. While partnerships have risen 15.3-fold during the past decade, capital deployment has grown only 1.4 times. Compare that to the 2.6x expansion of digital health investments. In 2024, FemTech secured $2.2 billion in funding, a sliver of the $26 billion digital-health pie.

This disparity isn’t due to a lack of innovation—quite the opposite. The problem is systemic: funding gaps, policy voids, and clinical blind spots that overlook the $360 billion “ghost market” of women’s health. That phrase— “ghost market”—is the report’s haunting term for the opportunities left untouched by current investors and providers alike.

From Fertility to Full Spectrum

One of the report’s most critical takeaways is how much the FemTech category is maturing. Fertility tracking and pregnancy apps put the field on the map. But FemTech today is far more.  It recognizes the vast need for medicine to engage with women’s unique health needs, long unaddressed.

The Galen Growth data shows that while gynecology and oncology account for more than half of all FemTech ventures, menopause, chronic pain, autoimmune conditions, cardiovascular disease and mental health are surging into the investment and innovation spotlight. These are not “niche” categories—they represent common, often underdiagnosed or misdiagnosed conditions that disproportionately affect women and impair their quality of life.

This expansion reflects a growing recognition that women’s health is not a subset—it’s a central pillar of public health. As de Salaberry writes in a soon-to-appear Health Tech World byline: “To be transformative, FemTech must address the entirety of the women’s health continuum, including those therapeutic areas that are not traditionally branded as female-specific but affect women in distinct ways.”

Twice the Clinical Evidence—But Still Under Scrutiny

Perhaps the report’s most sobering—and telling—data point is that FemTech ventures generate nearly twice the volume of clinical trials, peer-reviewed research, and regulatory filings as their digital health peers. Twice. That’s not due to past scientific rigor; these companies are held to a higher standard. Founders and advocates must go the extra mile to validate the clinical value of their solutions.

Despite this, systemic barriers remain. The report shows 71 percent of early-stage FemTech ventures struggle to raise a Series A round. Funding the “middle”—those post-seed but pre-scaleup companies—is an urgent priority. Without it, too many promising solutions will stall before reaching the women who need them.

Let’s be clear: this isn’t just about meeting investor milestones. It’s about delivering equity in care. Cardiovascular disease is the leading cause of death among women, yet it remains underrepresented in FemTech portfolios. Alzheimer’s and autoimmune conditions disproportionately affect women, yet receive comparatively little innovation focus.

Those are not oversight gaps. They are deep, systemic failures – disparities in our health innovation system.

From Direct-to-Consumer to Deep Health Integration

Another significant signal of maturity is the shift away from pure direct-to-consumer (DTC) models. In 2024, 42 percent of FemTech partnerships involved health systems, up from just 10 percent in 2020. That’s a tectonic shift from point solutions to systemic integration.

As de Salaberry puts it, “DTC strategies alone cannot reach underserved populations or secure the reimbursement pathways necessary for scale.” Systemic integration—through payers, providers, and public institutions—is essential for sustainability and access. FemTech must live where care happens, not just on consumers’ cell phones.

Regionally, the picture is just as telling, with Europe leading in clinical rigor, with 50 percent of FemTech ventures demonstrating proven clinical strength. North America leads in funding ($1.3B), while Asia-Pacific remains a hub of AI-driven diagnostics, even amid a dip in capital investment. These trends point to what’s next: a future driven by localization, clinical excellence and technology convergence.

Forces Shaping the Future of FemTech

The report outlines five key factors shaping the FemTech evolution during the next five years. They’re worth noting for anyone investing, innovating or advocating for equitable care with an eye toward return on investment:

• Redefining the Scope: FemTech must look beyond reproductive health to address chronic diseases, aging, and behavioral health.
• Breaking the DTC Mold: Success will be defined by integrated partnerships with employers, insurers, and health systems.
• Balancing Rigor and Agility: Regulatory requirements must support innovation without stifling it.
• Funding the Growth Gap: Series A and B support is critical to help early innovators scale.
• Smart Consolidation: M&A isn’t just about exits—it’s about building category leaders with breadth and credibility.

Infrastructure, Not Hype

The key here is infrastructure. FemTech is not a trend—it’s the scaffolding of women’s health innovation. Investors need to hear that message and invest to make this population health category viable.

With nearly half the global workforce made up of women, the ROI on women’s health is not just moral—it’s macroeconomic. The health ecosystem can no longer afford to treat women’s health as an edge case. It is, in fact, the core of population health.

FemTech’s next chapter will be shaped by evidence, equity and integration. It must also be underpinned by trust from payers, providers, and patients. That trust is earned through data, outcomes and the bold assertion that women’s health is health, full stop. This Galen Growth Report goes a long way to demonstrating the positive outcomes when innovation and investment converge.

As Julien de Salaberry wisely states: “The next generation of Femtech isn’t about visibility—it’s about value, integration, and health systems impact.” That’s not just a forecast—it’s a framework for what’s next.

[Editor’s Note: For a deeper dive into the Galen Growth FemTech 2025 report, visit galengrowth.com. The full report and press release, are available now.]

The post Galen Growth FemTech 2.0 Report: Elevating Women’s Health from Niche to Necessity appeared first on Medika Life.

Usually, detecting cancer is done through a combination of physical exams, imaging tests, blood tests, and biopsies. A biopsy, where a tissue sample is taken and examined under a microscope. This process is time-consuming and often relies on parts of the health system working together quickly, which does not always happen. Some cancers, like brain, pancreatic, and ovarian cancers, are difficult to detect, which can slow diagnosis even further.

By contrast, liquid biopsies can detect cancer more quickly. This type of testing looks at bodily fluids (typically blood) for evidence of cancer cells by finding biomarkers that are shed by cancer cells into the bloodstream. Liquid biopsy technology is advancing fast and with new technologies emerging, such as using light to detect these signals. This is a similar approach to that used when small swabs are passed over luggage and analysed at airport security.

By combining this spectral analysis with artificial intelligence (AI), it is possible to speed up cancer detection at a significantly lower cost. At the forefront of this revolution in cancer detection is Dr. Holly J. Butler. Dr Butler is the co-founder and CTO of Dxcover, the company behind the award-winning multiomic spectral analysis platform. Grounded in biophotonics and driven by an unwavering dedication to improving patient outcomes, Dr Butler is striving to bring about a new era of non-invasive diagnostics; one where a couple of drops of blood and a beam of light might one day save millions of lives.

Dr Butler, alongside an award-winning leadership and research team, has been developing methods to analyse blood samples using infrared spectroscopy. What they discovered was a way of ‘reading’ the biochemical fingerprint of disease in a standard blood test. This research became the foundation of an award-winning proprietary platform that leverages a unique combination of AI and spectral analysis to detect patterns in small blood amounts, allowing clinicians to find cancer earlier, more accurately, and far more affordably than many existing techniques.

The potential is enormous. Unlike conventional liquid biopsies, which rely on picking up fragments of tumour DNA, this platform is more wide-ranging in its approach. It uses a multiomic strategy – looking at proteins, lipids, metabolites, and more – through a process known multiomic spectral analysis. It translates to even tiny tumours, sized at just 0.2 cm, being capable of leaving a detectable trace. And it’s all done with just nine microlitres of blood.

Dr Butler’s drive to transform scientific ideas into reality started early. After her Ph.D., she took on a Scottish Enterprise-funded project to translate laboratory-based research into clinical diagnostics. Her entrepreneurial endeavours were making waves as early as 2017 – she was ‘Young Entrepreneur of the Year’ at the Scottish Women’s Awards and received the Women in Innovation award at the Global Game Changers Awards. She has continued to be a vocal advocate for women in STEM and an active mentor to early-career scientists and entrepreneurs via the Strathclyde Inspire network in the intervening period.

“I’ve always been drawn to problems where science can make a real, tangible difference in people’s lives,” she says. “To me, early detection for the most difficult to detect cancers is one of the biggest, most urgent problems we face – and one we hope to solve.”

Dr. Butler’s role in bringing this innovation along is as much practical as it is strategic. She is part of a team that spans lab operations, data, software, quality and regulatory affairs, pushing the science to clear the bars for real-world medical use. “You can’t just invent a technology,” she says. “You need to prove that it works, scale it with safety, meet stringent quality specifications, and prove how it fits into clinical pathways. That is the challenge.”

For Dr Butler, it is about the impact on lives. “Cancer still kills nearly 10 million people a year,” she says. “The difference between early or late detection can be life and death. We want to make early detection routine – not something that’s just for some individuals or comes too late.”

Now pursuing an Executive MBA, Dr. Butler is expanding her leadership credentials. “Science gave me the means to innovate,” she says. “But the MBA is teaching me to lead, to strategise, to build something that can last.”

That ecosystem, she hopes, will be one where innovation and inclusion go hand-in-hand. She’s particularly passionate about ensuring that diagnostic breakthroughs become accessible across communities. “We’re aiming for a future where your GP can run a test like this early—long before you’re even referred to a specialist,” she explains.

Dr. Butler’s work remains patient-centred and personal. “Every time we detect a cancer that would have been missed – that’s the goal,” she says. “And every time we improve the technology is a step closer to a world where fewer people have to hear the words, ‘if only we’d caught it sooner.'”

The post Shining a Light on Early Cancer Detection appeared first on Medika Life.

Imagine it’s the mid-1990s and the U.S. has decided to pursue policies that would restrict trade and investment to Asia instead of promoting it. Would those markets still prosper? Would the U.S. have grown as strongly or had the same counterweight to China if the American government had abandoned Indonesia, Vietnam, Thailand, Malaysia, Singapore or other regional markets?

At the time, these countries represented the next frontier of economic opportunity for American companies seeking to establish manufacturing and financial hubs, sell to millions of new consumers and tap an emerging talent base. Much of the economic data from the past thirty years underscores the mutual economic benefits that came from favorable policies that promoted deeper diplomatic cooperation and corporate investment in Asia.

I had a front row seat on this economic rocket ride early in my career, spending more than four years right after college working in international marketing throughout Southeast Asia. We have seen a tectonic shift in global trade since then, mostly resulting in incalculable benefits to global trading partners, including the U.S., as market access has opened for an array of goods and services. In combination with health systems investments, countries like Indonesia, which were once leading recipients of development assistance, have seen their GDPs increase to the point where they are now considered middle-income countries and are providing economic assistance to other countries in public health programs like the ones supported by Gavi, the Vaccine Alliance.

This sort of massive transformation came about because the U.S. and other countries played the long game. It’s crucial to keep this in mind – and the hypothetical scenario of where we would be today if we had lopped off trade opportunities with Asia 30 years ago – because we are about to retreat from the next great frontier market of the 21st century: Africa.

The implications of such a move are reflected in economic and demographic data. Eleven out of the top 30 fastest-growing economies in the world last year were in Africa. A staggering 70 percent of the population is under 30 years old, a tsunami of innovators, entrepreneurs, researchers and everyday workers hungry to supercharge their futures. In health, education, financial services, technology, manufacturing and many other sectors, African markets are showcasing new models that can help emerging economies leapfrog in their economic development.

It’s a big reason why China, India, the Gulf States and many other countries are racing to establish economic partnerships with key African markets so they have an established presence as the region becomes more prosperous. But the United States is opting out.

Currently, plans developed by the Trump Administration to reorganize the State Department indicate an intention to scale back the American diplomatic presence substantially in Africa. This follows the dismantlement of USAID, de-funding of PEPFAR and other key public health programs, and the anticipated scuttling of the Africa Growth and Opportunity Act (AGOA), a vital trade agreement that allows for duty-free access to the U.S. for many African exports.

The result of these cuts could leave the U.S. government and companies sidelined from any meaningful diplomatic engagement and commercial gains as African markets race ahead with support from our greatest geopolitical rivals. Without robust engagement from American embassies, U.S. companies may be hobbled as they seek to create commercial partnerships, understand the competitive landscape of key African markets, negotiate regulatory barriers and navigate legal and operational threats that arise in any market.

Such a shutout may be felt acutely by American biopharmaceutical companies and health start-ups that include African markets in their clinical trials, partner with national governments and civil service organizations on early-market initiatives, attract talented scientists and build brand loyalty with more than a billion new health consumers. Policy and regulatory issues in Africa are routine problems that healthcare companies work with American embassies to solve, along with risk management.

Then there is the potential cost to domestic U.S. healthcare from cutting global health programs and diplomatic presence in Africa. USAID offices were often attached to American embassies and have been among the first to respond to the early detection of disease outbreaks. The U.S. spent $900 million in 2023 to fund laboratories and emergency preparedness and response in more than 30 countries, many in Africa. Those programs are now on hold, which increases the danger that outbreaks of polio, Ebola, Marburg, and mpox, as well as bird flu, could erupt. Without that frontline defense, the risks grow dramatically higher for existing and new diseases to reach Americans at home and overwhelm our health systems.

It’s become cliché to say “health there affects health everywhere,” but when more than 77 million people travel to the U.S. from foreign destinations in 2024, it’s obvious that humans are the greatest vector known to disease. America’s massive biomedical research capacity and our biopharma companies are at the vanguard of protecting our health. Abandoning our political and commercial connection to key countries in Africa reverses years of important progress.

We depend on access and cooperation with Africa’s emerging markets to help maintain our health defenses and build a next generation drug pipeline, but also to create a pathway to future economic growth. Without the vital support our companies receive through U.S. diplomatic assistance, that pathway could be closed off. Are we prepared to risk that?

The post Retreating from the Opportunity of a Century appeared first on Medika Life.

According to the report, global investment in Consumer Health Technology grew by 9% in 2024, totaling $4.5 billion. This increase reflects investor confidence in technology-driven health solutions and signals a shift toward consumer empowerment. However, despite the surge in funding, the report underscores persistent challenges, including a clinical validation gap that could hinder long-term adoption and trust.

“The Consumer HealthTech sector is at a pivotal moment,” said Julien de Salaberry, founder and CEO of Galen Growth. “We are witnessing the continued health-sector evolution where consumers seek to secure stronger ownership over their health and well-being. People who succeed in using their buying power to secure innovation with clinical validation will shape the future of health.”

Investment and Market Dynamics

Galen Growth’s report reveals a complex funding environment where record investment is contrasted by uneven access to capital. While total investment rose to $4.5 billion in 2024, the market remains heavily weighted toward early-stage ventures:

• 75% of Consumer HealthTech ventures are still in the seed stage, highlighting the challenge of securing Series A and beyond.
• Only 25% of ventures incorporated in the last seven years have progressed to Series A or beyond.
• 11 mega deals (valued at over $100 million) accounted for 37% of overall funding, reflecting investor appetite for mature ventures with proven models.

Regional Investment Trends

North America remains the dominant market, capturing 64% of total funding and securing 78% of global venture capital deals. The region’s leadership in funding reflects its mature digital health ecosystem and strong investor appetite for high-growth, technology-driven health solutions.

Europe attracted 24% of global funding, focusing on corporate health and wellness solutions. In contrast, the Asia-Pacific region secured 12% of international funding, driven by increased investment in preventive health marketplaces and telemedicine.

Notable Deals from 2024:

• Neko Health secured a $260M Series B for its AI-driven preventive health model, which is focused on early detection and personalized treatment recommendations.
• eGym, a global fitness technology leader, raised $201M in a Series H to expand its connected training platform and enhance its AI-powered coaching system.
• Spring Health, a mental health platform, raised $100M in a Series E to scale its personalized therapy and mental wellness offerings.
• Flo Health, a women’s health app focused on menstrual cycle and fertility tracking, raised $200M in a Series C to expand its product offerings and global reach.

Mental Health Takes the Lead

Mental health emerged as the dominant focus in Consumer HealthTech in 2024, attracting 29% of total funding—underscoring the growing recognition of mental well-being as a vital part of overall health.

“Consumer HealthTech has the power to democratize health by giving individuals greater control over their health,” added de Salaberry. “But for this potential to be realized, ventures need to address the division between the haves and have-nots and the clinical evidence gap to demonstrate measurable health outcomes.”

The rise in mental health investment reflects a shift toward more personalized, technology-driven care models. Consumers increasingly expect the same level of convenience and personalization in health that they experience in other industries, such as retail and finance. This demand has spurred innovation in teletherapy, mental health apps, and AI-driven cognitive behavioral therapy.

Key Therapeutic Areas:

• Women’s Health saw a surge in funding, capturing 20% of total investment. Startups like Flo Health are capitalizing on the growing demand for reproductive health and fertility tracking.
• Preventive Health attracted 17% of funding, driven by the rise of AI-powered diagnostics and real-time health monitoring.
• Sleep and Cognitive Health solutions are also gaining traction as consumers seek to improve overall well-being through better sleep quality and cognitive enhancement.

Strategic Partnerships and M&A Activity

Partnerships and consolidation play a critical role in the sector’s growth:

• More than 900 new partnerships were formed in 2024, signaling growing collaboration across the health ecosystem.
• Venture-to-venture acquisitions accounted for 79% of M&A activity, highlighting how companies are using consolidation to strengthen market presence.
• Notable partnerships included:
  • Pfizer partnered with GoodRx to improve medication management and strengthen direct-to-consumer outreach.
  • Amazon expanded its mental health footprint through a strategic partnership with Talkspace for teleconsultation services.
  • Mayo Clinic partnered with Prenetics to advance genomics-based health solutions and expand access to precision medicine.

This trend toward consolidation reflects increasing pressure to scale solutions and navigate complex regulatory and reimbursement landscapes. More prominent players are looking to leverage established consumer brands and data platforms to enhance their competitive positioning.

Issues and Prospects

Despite the rise in funding and market activity, the Consumer HealthTech sector faces critical challenges:

• Clinical Validation Gap: The report highlights that Consumer HealthTech ventures exhibit an 11% lower clinical evidence signal than the broader digital health ecosystem. This gap raises concerns about scientific rigor and long-term adoption.
• Funding Bottleneck: Early-stage ventures struggle to secure Series A funding, with most capital concentrated in late-stage deals.
• Accessibility and Equity: Unlike traditional health, which is often covered by insurance, Consumer HealthTech solutions rely heavily on out-of-pocket spending. This creates a divide between those who can afford premium health services and those who cannot.

“The health sector cannot afford to become a system of haves and have-nots,” said de Salaberry. “Consumer HealthTech ventures must work to close the accessibility gap by developing affordable solutions and proving their clinical value.”

Future Trends and Market Outlook

The Galen Growth report identifies several key trends shaping the future of Consumer HealthTech:

• AI-Driven Personalized Medicine: AI-powered diagnostics and health assistants enable hyper-personalized treatment plans based on genetic, biometric, and behavioral data.
• Hybrid Models: Successful Consumer HealthTech ventures increasingly integrate with traditional health systems to improve credibility and adoption.
• Regulatory Oversight: Governments and regulators will likely increase scrutiny over health claims and data privacy, creating startup opportunities and challenges.
• Equity and Affordability: To achieve long-term impact, Consumer HealthTech solutions must address disparities in technology access and affordability.
• Digital Therapeutics: Prescription-based digital interventions for managing chronic conditions are poised to bridge the gap between technology and evidence-based care.

A Defining Moment for Consumer HealthTech

Consumer HealthTech represents a seismic shift in health—moving from reactive to proactive care. As Galen Growth’s report reveals, the future of health lies in empowering individuals with technology-driven solutions that provide real-time insights and personalized care.

The rise of AI-driven diagnostics, wearable technology, and telemedicine enables consumers to monitor and manage their health in real time. This shift toward preventive care improves outcomes and reduces the burden on traditional health systems.

However, sustainable growth requires stronger clinical validation and deeper integration with established health frameworks. Consumer HealthTech ventures must navigate the complexities of reimbursement, regulation, and market competition to secure long-term success.

The Galen Growth report makes it clear: The future of health belongs to those who empower consumers—and prove it works.

The post Consumer HealthTech: A Data-Driven Evolution in Health Engagement appeared first on Medika Life.

What’s more, exercise is just not for your muscles and your strength. I’ve written on why muscles are involved in mood and you can go to this article to refresh your memory or read it if you haven’t already.

What recent research benefits those over 70? Undoubtedly, we have a great deal more in terms of input in our muscle maintenance than anyone thought when they considered people over 70. The newest research refutes that myth, providing new insights and amazing changes for this group.

But there are specific periods in our lives when certain changes will begin, and with each phase, there will be almost undiscernible changes. However, there are indications that those above 70, who are at greatest risk for instability, balance, problems, muscle weakness, and even bone fractures, require our attention. Previously, adequate work was not directed at the potential maintenance and retrieval of muscle strength in this group, and that is where new, exciting research is coming to the fore.

What Are the Groups?

Sarcopenia is the medical term for muscle loss, and it is a normal aging process that affects all humans, although the rate of onset and the severity of the condition is different among individuals. This slowdown in muscle mass, strength, and function has implications for the quality of life and dependence of the elderly. Muscle loss occurs at different ages and we need to pay attention to enable people to prevent or at least remediate this to some extent.

20s-30s Age Group

In the young adulthood (20s to 30s) age group, muscle mass is at its peak. This age group is likely to have the best muscle strength and function as most people. The body is well equipped to build up and preserve muscle tissue as long as the muscle is used and fed properly. However, even at this young stage, people with sedentary jobs may already experience some muscle atrophy that does not manifest itself clinically. It sets the stage for future deterioration, so appropriate physical activity and diet during these years are a sound investment into future muscle health.

40s Group

Beginning in the 40s, the person begins to show some changes as mentioned above. The literature reviews indicate that muscle mass starts to decline at about 0.5–1% every year after age 30 and the rate increases a little in the 40s. It is also the time when strength reduction is first noticed especially in muscle fibers which control power and speed.

The quadriceps, hamstrings, and calf muscles may start to weaken, especially in people with low levels of physical activity. Most people in this age bracket feel the fatigue and reduced physical endurance when engaging in physical activities.

50s Group

More specific features of muscle atrophy can be observed in the 50s. The rate of loss is higher, currently ranging between 1–2% every year. At this time, the hormonal changes worsen the muscle regeneration. To women menopause reduces the level of estrogen that accelerates muscle loss. Men also have low levels of testosterone that also worsen the muscle tissue.

The abdominal muscles and the lower back muscles, which are the stabilizers, also weaken a lot. Upper body strength, especially in the chest, shoulders, and arms, decreases at a higher rate than before.

60 Group

In the 60s, the loss of muscle is higher and the following rates are observed: 2–3% per year. The consequences of the changes are seen in the everyday life and the person needs help in performing certain actions. The muscles of the lower limb that include the quadriceps, hamstrings and gluteal muscles also weaken greatly.

Many people in this age group will report having problems with stairs, getting up from a chair, or walking for long distances. The hand grip strength is reduced which in turn affects the fine motor skills and the ability to handle objects. The sense of balance is also affected because muscle weakness and neurological changes in proprioception occur.

Over 70 Group

Muscle loss is at its highest in adults over 70, with annual losses of 3–5% if no schedule for slowing or reversing this loss is introduced. This accelerated decline has a major effect on the quality of life and independence. This age group has distinct muscle weakness with well-defined patterns of muscle involvement that have important functional implications

The quadriceps, hamstrings and gluteal muscles are the extremity muscles that are affected in a greater degree. This weakness is manifested as:

1. Difficulty in rising from sitting position
2. Slow walking
3. High chances of falling,
4. Difficulty in climbing stairs. The ankles are also liable to weaken, and this causes the client to have difficulty with walking and increased chances of falling.

Strengthen these muscle groups by including functional exercises that may involve using body weight, resistance bands, or light weights. Of course, any exercise routine in any age group should always be planned with a certified trainer or someone in a rehabilitation facility specifically to address these needs.

Some of the exercises that can be of great help include; standing from a chair, slow walks, sitting leg raises, and ankle exercises to build strength. Exercises in water are an excellent way to work on these muscles with minimum impact on the joints.

Balance is trained very effectively by standing exercises that reduce the base of support step by step. The tandem stance is particularly effective — this is when one stands with one foot in front of the other, heel to toe, to begin with, leaning on a sturdy chair or counter. In the event that stability improves, the support can be reduced to fingertip touch, then to no support at all.

The single leg stance is another basic exercise; start by holding a chair and lift one foot slightly off the floor for 10–15 seconds and then switch to the other side. This exercise directly strengthens the stabilizing muscles around the hips and ankles that are crucial for the prevention of falls.

Weight shifting exercises are used to develop the dynamic balance. The weight shift is to stand with feet hip width apart and then slowly shift weight from one foot to the other without moving the feet. Clock reaches expand on this by visualizing standing at the centre of a clock face and reaching one foot towards different ‘hours’ whilst remaining balanced. These movements enhance proprioception, which is the sense of where the different parts of the body are in space, and this sense is often reduced as one gets older.

The good news is that even though you have lost muscle strength, there is still the ability to help your muscles, pull back some of that strength and renew your ability to move and continue an active lifestyle. As has been noted by several of the articles, water exercises seems to be one of the best, especially for anyone with arthritic conditions. And, don’t forget that exercise is intimately associated with mood.

The post Strength Beyond Years: How Exercise Redefines Aging appeared first on Medika Life.

In the year and a half I worked in that department, I learned more about medicine, human rights, patients’ responses to loss, and the ambivalent relationships of medical personnel than throughout my entire medical work history and career as a nurse.

Although I later moved on to direct care positions in multiple departments (OB and surgery, Mother/Baby/PP, Med-Surg, Trauma), the emergency room experience was my formal introduction to many foundational aspects of the medical environment, especially regarding the unaddressed conflict in the relationships between the differing roles of providers in medicine.

The main concerning dynamic I observed was that nurses were generally dismissed and disregarded by many physicians, as both professionals and as necessary components in the practise of medicine.

In my experience as a professional, this aspect has still not changed over time and spans throughout all specialties in medicine.

When I became a nurse in the year 2000, I was no longer just the observer of adverse or lack of communication toward nurses from physicians or the frequent poor treatment of physicians toward nurses. I became the receiver of both.

Nursing Expertise Is Still Mostly Misunderstood

Many physicians do not see the nursing staff as an imperative extension of their own care and knowledge. Many are unaware of what most nurses do and how much they know. They do, in fact, just expect their orders to be carried out and quite often neglect to understand the gap that nurses must close from orders of care to implementation of care and then to continued follow-up of care. The latter two skills are what create and sustain patient health and wellness.

Nursing responsibilities, experience and skills remain a neglected and misunderstood facet of healthcare. Most lay people see nurses as the medical personnel carrying out their doctor’s orders, making the necessary calls to patients and hopefully, effectively understanding the medical reasoning and intricacies behind the care and information they are delivering.

However, true nursing goes beyond this.

Learning to regurgitate orders and instructions is not what gets a good nurse through school or what keeps his/her patients alive. Critical thinking, research, and observation while responding appropriately in and to emergent, acute, and chronic situations, listening when no one thinks we are listening, and knowing when the wrong medicine or treatment has been ordered or recommended are.

The doctor will not go to jail if the nurse gives an inaccurately ordered medication, resulting in an adverse event or fatality; it is the nurse.

We are, first and foremost, the buffer between a physician and his patient.

And both patients and physicians need this.

What Effective Nursing Offers To Physicians’ Care of Their Patients

Good nurses listen to their patients and have a knack, not just the training for, for excellent triage. Body language tells more than a patient’s report. Patients’ verbal reports must be delicately and discreetly screened for hidden information that is critical in many cases, to appropriate safe care and orders. Nurses hone in on things not said, or that are mis/underrepresented, which often results in a totally different approach to treatment than at first written.

Nurses’ bedside experience yields a wealth of information and patient history that frequently change the initially documented needs and treatment of the patient’s condition. The following are some common examples: (Note that global and national MyChart EMR records now give access to patient medical information and have greatly improved providers’ knowledge of documented patient information.)

1. A patient comes into the emergency room or the clinic reporting a “terrible headache” and is nauseated and dizzy but denies a history of hypertension. Vital signs reveal a dangerously high pressure, but the patient defines themselves as non-hypertensive because they are normally prescribed hypertensive medications, so they consider themselves “cured.” This is a much more common thought process than is understood, especially for elders.

Further nursing triage reveals that the patient is “between” PCPs (very often this is code for the patient’s dislike for their previous one and so they just quit going to visits) and the patient has been out of their medication for two months (due to an inability to cover changing Medicare/other insurance costs). This knowledge prevents the ordering of further hypertensive medications (for perceived acute/undiagnosed episodes) by the ER physician or urgent care clinic doctor which could cause a dangerous drug interaction and/or overdose because the patient is very likely to refill the original medication as well at a later date. This is another common problem among elderly patients, especially. Gaining a full picture of the patient’s circumstances in this situation will also predicate running lab tests which may have not been ordered otherwise or ordered differently. This would offer additional insight to the patient’s current cardiac and renal status/risk in association with current signs and symptoms.

Nursing also contacts the inhouse social worker to assist the patient in funding available to cover the cost of medications and to elicit a list of PCP’s in the immediate area that take patient’s insurance (this is providing SW is as thorough as expected.) Nursing also provides a follow up call a few days after the visit to ensure that patient has had their needs addressed.

2. Patient presents with guarded abdominal pain. Their eyes are dark, their pupils pinpoint, and they are jittery and talking fast. The nurse notices skin irritations and sores and a “slack jaw” appearance in the patient. Many physicians immediately write this patient off as an addict, document “drug-seeking behaviour” as cause for visit and stop there. This has been both my personal and professional experience. Given the patient’s appearance which concurs with heroin/meth addiction, this may be a correct standing diagnosis. However, there is always more to know and investigate. This patient is a human being in need of care and thorough assessment. The pain the patient complains they have often has another root source besides withdrawal. The nurse notices after the doctor leaves the exam room that the patient winces when standing and limps on the right side. An astute nurse will pull the physician back in and subsequent due diligence medically reveals appendicitis. A life is saved.

*A more frequent finding with patients in addiction is bodily injury due to violence perpetrated against them from the population they associate with. Since shame is a huge factor in this group, the patient will often not divulge a criminal act against them and associated injury is easily missed in assessment.

3. Patient complains of generalized dizziness and imbalance. She mentions that she notices one side of her body seems to be “lagging.’ The neurological “tug” test is performed along with the routine balance test. No present abnormalities are observed, yet the patient insists she is experiencing increasing episodes. Although labs are ordered to check for abnormalities in hydration, glucose, and possible tell-tale results of a recent stroke or myocardial infarction (cardiac enzymes and CRP), they come back normal. As the physician is writing discharge orders for PCP follow-up recommendations, the nurse checks in with the patient.

The patient is sitting with her head down. Her off-handed mumbled comment catches the nurse’s attention. “I feel like I’m literally living in darkness and am scared most of the time.” This comment strongly hints at mental health issues. Adverse mental health conditions that are left untreated will absolutely affect the body (altered stature, weight balance, gait, eye movement, posture, cognitive word halt/jumble.) Upon further assessment, the patient also reveals long-term anxiety-related insomnia, one hallmark (though not entirely definitive) of compromised mental health.

A discussion with the doctor now adds a psych evaluation, a mental health consult to her PCP follow up and community referrals. The patient’s time is not wasted reaching out to the medical community because a nurse made the decision to follow the cornerstone of his/her medical training to observe/listen to the patient. Nurses are taught to observe both the presence and absence of information and body language and many other factors. The picture presented when first meeting a patient is most often just the tip of the iceberg.

The Benefits Of Honoring and Respecting One Another as Providers

When physician and nursing roles support and complement each other’s expertise and knowledge, and each respects the other’s insight and practice, great results occur for patients:

• a much more in-depth picture of the patient’s overall physical and mental health is revealed.
• potential risks and needs that often go unidentified are exposed.
• the patient receives a much more comprehensive, relative treatment plan.
• patient trust in the medical community increases

Better patient health is achieved, and a much-needed deeper level of patient trust in their care team begins to be restored.

Unified medical forces create reliability and safety for all involved.

Patient compliance is directly related to patient trust for their provider.

When physicians respect the nurses they work with and understand that good nursing staff are an immeasurable source of support and diverse medical knowledge, the target of healthcare, patients, benefit the most.

They are why there are doctors and nurses in the first place.

The post How Physicians Benefit From The Experience and Knowledge of Nurses appeared first on Medika Life.

If she does not get medicine on board immediately with symptom onset, days of misery ensue.

Migraine is a debilitating neurological disease that affects over a billion people worldwide, with those assigned female at birth significantly more likely to experience it than men (21 versus 10 percent).

This common condition often hits young people the hardest, leading to missed days at work and school, reduced productivity, increased errors, and presenteeism (being present but not fully functioning due to illness).

Today, I’ll briefly explore a new nasal spray for those suffering from migraines.]

Background

Migraines can knock someone out of commission.

Symptoms such as nausea, pain, and light sensitivity can render it impossible to work or care for family members.

Migraine is the leading cause of disability among women.

Many people suffered migraines, including Julius Caesar, St. Paul, Thomas Jefferson, and Charles Darwin.

My friend is one of many searching for better migraine management options.

First, I cannot resist looking at the historical record.

A Brief History of Migraines

The ancient Egyptians described migraines and nerve pain.

Hippocrates (460–370 BC), the father of medicine, was the first to document migraine scientifically.

“A bright light in the right eye, followed by the onset of severe pain in the head, which eventually extended to the entire area.”

Let’s turn to the breakthrough.

A Nasal Spray for Migraines: Timolol

There are many migraine medications, but they sometimes are not very effective, have high costs, or associated side effects.

Migliazzo and Hagan published the first case series of long-term success in treating acute migraines with timolol eye drops.

Timolol eye drops bypass the digestive process when applied to healthy eyes.

They rapidly travel through the tear ducts to the nasal passages, where absorption by the nasal mucosa rivals the speed of intravenous injection.

A nasal spray makes sense since the mechanism of action is through the nose (and some have trouble using eye drops).

Nasal Spray Study

Researchers had a national compounding pharmacy create a nasal spray device to deliver Timolol.

Patients spray each nostril quickly at the first onset of headache.

If symptoms persist, they can repeat the spar 10 to 15 minutes later, with a maximum number of sprays found in 24 hours.

No one on beta-blocker medicines was offered the spray.

Nasal Spray Results

Here are the results of a small series of 16 patients with refractory migraines:

Ten patients (63 percent) reported being pleased with the nasal Timolol and added it to their preferred treatment.

There were no significant side effects.

My Take

A National Headache Foundation survey indicates that the majority of individuals with migraine are unable to control their disease and are dissatisfied with current preventive treatment options.

We must do better.

The reported series on nasal timolol is remarkably small.

Concerning safety, Timolol has been approved for glaucoma, many cardiovascular conditions, and migraines for over 40 years, and it has a long track record of safety.

If you have acute migraine headaches that are not responding satisfactorily to standard medicines, nasal spray timolol 0.5% may offer you another option.

Finally, the study authors offer this:

“A huge advantage of this treatment is that it is presently available from O’Brien Pharmacy in Kansas City and Bayview Pharmacy in Rhode Island by prescription. The formulation has been published in the International Journal of Pharmacy Compounding, so other local compounding pharmacies should be able to prepare it.”

The study authors indicate they have no financial conflicts.

The post New Hope for Migraine Sufferers: Could a Simple Nasal Spray Be the Answer? appeared first on Medika Life.

Many of my patients have recently been asking me what it means to have dense breasts.

They sometimes carry a letter saying that their mammograms showed heterogeneously (or extremely) dense breast tissue.

The U.S. government now mandates that radiologists report breast density on mammogram reports but offers no guidance on how to do so.

In this Breast Cancer Awareness month, I want to provide some information about the implications of having dense breasts.

Breast Density Reporting

Beginning September 10, 2024, the U.S. government mandated this:

“Mammography facilities must provide all patients receiving a mammogram with one of two Federal breast density notification statements (either “not dense” or “dense”).“

Additionally, the mammogram report sent to referring providers must include an assessment of the patient’s breast density.

Defining Breast Density

Dense breasts are a mammographic finding in which the breast tissue appears more glandular or fibrous relative to fatty tissue.

The breast comprises two types of tissue: glandular tissue, which produces milk, and fatty tissue, which provides support and cushioning.

Dense breasts contain more glandular and fibrous tissue and less fatty tissue, which makes them appear denser on a mammogram.

Four Categories of Breast Density

The American College of Radiology classifies breast density into four categories:

1. Almost entirely fatty: The breast comprises fatty tissue and is the easiest to read on a mammogram.
2. Scattered areas of fibroglandular density: Although some areas of glandular and fibrous tissue exist, the breast is still considered primarily fatty.
3. Heterogeneously dense: There are many glandular and fibrous tissue areas, and the breast is considered moderately dense.
4. Extremely dense: This means the breast is very dense, with a lot of glandular and fibrous tissue.

Patient Notifications

A radiologist — a doctor who reads your mammogram — assigns your breasts a density.

As noted above, s/he will place each mammogram into one of the four breast density categories.

Your mammogram report may offer these observations:

• If NOT DENSE: “Breast tissue can be either dense or not dense. Dense tissue makes it harder to find breast cancer on a mammogram and also raises the risk of developing breast cancer. Your breast tissue is not dense. Talk to your healthcare provider about breast density, risks for breast cancer, and your situation.”
• If DENSE: “Breast tissue can be either dense or not dense. Dense tissue makes it harder to find breast cancer on a mammogram and also raises the risk of developing breast cancer. Your breast tissue is dense. In some people with dense tissue, other imaging tests and a mammogram may help find cancers. Talk to your healthcare provider about breast density, risks for breast cancer, and your situation.”

Let’s turn to the implications of breast density.

Breast Density Distribution

The American College of Radiology (ACR) observes the following population distribution of breast density:

About 10 percent have almost entirely fatty breasts. At the other extreme, 10 percent have extremely dense breasts.

Eighty percent fit into one of the middle categories.

What causes dense breast tissue?

It’s unclear why some women have dense breast tissue while others do not. You may be more likely to have dense breasts if you:

• Are younger. Breast tissue often becomes less dense with age.
• Have a lower body mass index. Individuals with less body fat are more likely to have dense breast tissue than women who are obese.
• Take hormone therapy for menopause. Those taking combination hormone therapy to relieve signs and symptoms of menopause are more likely to have dense breasts.

Breast Density Implications

Having dense breasts may increase your chances of getting breast cancer.

Moreover, dense breasts make it more challenging for radiologists (and their artificial intelligence friends) to spot cancer on mammograms.

Unfortunately, dense breast tissue appears white on a mammogram.

Lumps, both cancer and non-cancer, often appear white, too. I often say to my patients that dense breasts make it like you are looking for a snowball in a snowfield.

In summary, dense breasts can raise cancer risk and make mammograms less accurate.

Mammograms Are Still Important

First, while many of my patients with dense breasts initially think that mammograms are useless for them, mammograms are still a part of routine imaging.

After all, mammograms are the only medical imaging screening test proven to reduce breast cancer deaths.

Each week, my radiology team finds cancers on mammograms in women with dense breasts.

What Else Can You Do?

That said, here are some tactics you can use:

• Get digital breast tomosynthesis (DBT or 3-D mammograms). DBT creates breast images in slices from many angles, making abnormalities easier to see. Tomo mammograms increase the number of cancers discovered without other imaging.
• Consider ultrasound and magnetic resonance imaging (MRI). These advanced imaging approaches can help find cancers that a mammogram doesn’t indicate. However, breast MRI and ultrasound show many more findings that aren’t cancer (false positive), resulting in added testing.
• Know your breast cancer risk. We have many calculators (varying in complexity and weighing different factors — including family history).

There is no national standard for following up on dense breast reports.

Screening Recommendations

The American College of Radiology suggests that you talk with your healthcare provider and discuss your breast cancer risk.

Even if you have a low breast cancer risk (and have fatty breasts), you should get annual mammograms beginning at 40.

The U.S. Preventative Task Force recommends that all women get screened for breast cancer every other year, starting at age 40 and continuing through age 74.

The Real Problem

Radiologists must describe breast density on your mammogram report.

However, we don’t know what to do with this information.

For example, the American College of Radiology and the National Comprehensive Cancer Network recommend that women and their doctors consider supplemental screening.

On the other hand, the American College of Obstetricians & Gynecologists and the U.S. Preventive Services Task Force offer there is insufficient evidence of benefit to recommend additional tests.

Additional tests can detect more cancers than mammograms alone. However, we have no evidence that extra testing saves lives.

And This

Some studies raise concerns about the reliability of the system used to label breasts as dense or not dense.

A review article in Annals of Internal Medicine reported that radiologists reclassified up to 19 percent of women into a different breast density category — from dense to non-dense or vice versa — on their subsequent screening mammogram.

For those with dense breasts, we don’t know with certainty what the best practice is at this point.

The post Dense Breasts: The Hidden Risk You Can’t Ignore appeared first on Medika Life.

How many types of love do you think there are? Most of us might say the love of children, parents, friends, lovers, and even our country, but would that encompass all the love researchers are finding? We need to understand the concept of love and how it affects us physically and, as a result, emotionally.

Different love affects different areas of the brain and different neural transmitters—those pesky little chemical messengers that make it all possible. If we can boil it all down to neurotransmitters, are we then predicting that there might be something as simple as the words in that song, “Love Potion Number Nine?” Do we need to find Madame Rue and her herbal concoctions? Or do we need to use more sophisticated means of stimulating love? As some researchers believe, are there six, seven, or ten different loves? Here’s where the complexity enters the stage.

Certain research also suggests the common belief that “love is blind” is true. According to research, the brain’s attachment and reward networks are activated when we experience maternal and romantic love. Similar to how these ancient brain areas are involved in parental caregiving and long-term bonding in other mammals, they are also involved in these processes in our species. When we love something, is it neurologically the same as loving nature or our child?

Six Types of Love

Researchers, using story simulations and MRI technology, have concluded that love objects stimulate multiple areas of the brain. This discovery reveals six different types of love based on the target of affection.

Feelings of love for six different objects asserted are: 1. romantic partners, 2. one’s children, 3. friends, 4. strangers (varieties of interpersonal love), 5. pets (interspecies love), and 6. nature (nonsocial love).

How does the brain decide which are to stimulate to provide the appropriate type of love specific to that object? Three partially overlapping brain networks make up the “global human connection system”: the reward-motivation system (i), the embodied simulation/empathy network (ii), and the mentalizing system (iii).

This system categorizes closer affiliative relationships (parent-child, romantic, and friend) according to three factors: salience, social cognition, and social reward.

There are subtle differences between close interpersonal relationships — especially romantic and parent-child love—and more remote kinds of love for strangers, pets, and the natural world, according to stories and recordings provided by MRI. Interpersonal love of all types stimulated brain parts linked to social cognition, or “theory of mind.” The domains of reward and social cognition, as well as those connected to compassion or altruism, seemed to be implicated in the love of strangers. Owners of pets exhibited brain activity comparable to that of interpersonal affection.

Pets, too, play an important, integral role in these love relationships. Research to date has shown this to be true. Strong social ties and love are well-known to act as buffers against adversity. Humans and animals frequently develop close relationships.

A dynamic and mutually beneficial relationship between people and animals is called the “human-animal link.” Whether pets are beneficial to people’s health and well-being has long been a source of debate in human-animal interaction (HAI). At present, inquiries focus on who, what, and why questions for certain situations and not for others.

What About Singles?

Many types of love exist, and, in fact, even those who are not romantically attached at the moment, i.e., single, can be segregated into distinct groups, where some are happier than others. So being single does not mean you are either lonely or unloved.

The 4,835 adults who were unattached at the time of the study ranged in age from 18 to 65. The poll found ten different subsets of singles, with some subsets reporting higher levels of happiness than others.

One in five adults who were single reported being overjoyed. Their level of happiness was identical to that of the happiest couples in previous research. The survey revealed that 40% of the singles were satisfied, 36% were somewhat satisfied, and 10% were very unhappy.

The majority of singles, contrary to common belief, reported high levels of happiness and life satisfaction. Therefore, contrary to popular belief, being single can be just as fulfilling as being in a committed relationship, dispelling the myths that surround being single.

Is love complicated? Undoubtedly, it is more involved than we may have previously considered it to be. Depending on the type of love involved, it engages unique and interconnects networks sections of the brain. Some portions of our love are based on reward areas, while others are more involved in altruistic connections.

One area of love researched by many is that of pets and their place in our lives as not only objects of love but seemingly, aids in resilience and helping when adversity comes into our lives.

The post Love’s Not So Simple, and the Complexity Is Mindboggling appeared first on Medika Life.